About Ono

Management Policy

(1)Corporate philosophy and policy

The Group is "Dedicated to Man's Fight against Disease and Pain." Under this corporate philosophy, we are committed to fulfilling unmet medical needs. We aim to develop innovative new drugs that deliver true benefit to patients. We are highly aware of our responsibility as a pharmaceutical company dealing in medicinal drugs upon which human lives depend, and we are working to further strengthen our level of compliance to ensure that all our actions not only fully comply with all legal regulations but also are based on higher ethical standards.

(2) Business Model

To achieve sustained growth in a tough and complex business environment, we believe we have to focus our finite management resources on discovering and developing new drugs as an R&D-based pharmaceutical company specializing in prescription medicines.
ONO’s business model we pursue is not only to take up the challenge of discovering our own innovative drugs, but to develop in-licensing promising new candidate compounds from around the world.

. ONO’s Challenge of Discovering and Developing Innovative Drugs
We discover and develop novel drugs based on the “Compound-Orient” approach by collecting a library of compounds that may act on various therapeutic targets such as lipids and enzymes, and, through screening the library, identifying new drug candidates that would lead to treatments against disease. Based on our unique approach in discovery research, we focus our resources on the R&D efforts for cancer, autoimmune disease and neurological disease. We have specified these areas that have high medical needs as our priority R&D areas. We also focus on novel technologies including cell therapies and macrocyclic compounds, to keep tackling the challenge of drug discovery.
In addition, we are driving open innovation through the adoption of world-leading technologies and knowledge including research collaborations with world top-class scientists as well as many drug discovery collaborations with biopharmaceutical companies with leading-edge technologies to discover new drug candidates.
We will continue to work toward drug discovery and development to provide new treatment options with innovation to the frontline of healthcare, focusing on cancer, immunoregulation, and neurological disease by maximizing our open innovation strategy on a global basis.

. Licensing Activities
We vigorously pursue in-licensing of new drug candidates, in addition to in-house drug discovery, for stable expansion of our development pipeline for the future. The disease areas we concentrate on include oncology and supportive care in cancer, diabetes, and niche areas. In these areas, we aim at in-licensing of new drug candidates that have high value in terms of corporate strategy and efficiency.
For our global business, excluding Asia, with specially our new drug candidates developed in-house, we adopt a basic strategy of licensing out on a per-developed-compound basis to our partners, which have outstanding development and commercialization capacities.

(3) Growth Strategies

Under our corporate philosophy,  “Dedicated to Man’s Fight against Disease and Pain,” we drive activities in six priority areas, committing to our vision of turning ONO into what can be called a Global Specialty Pharma. We have established four growth strategies for sustained growth and are accordingly taking measures to satisfy as-yet unmet needs.

(a) Maximizing Product Value
Through active R&D efforts, companywide collaboration and enhanced HR training capacity, we will achieve expedited market launch and additional indication approval and peak sales in the shortest period from launch. In addition, we will develop a strategy formation that constantly ensures competitive advantage by adjusting with agility to environmental changes in each stage of the product life cycle. We will thereby maximize the potential of every product we offer.

(b) Game-changing R&D
Based on our original drug discovery approach “Compound-Orient,” we have specified cancer, autoimmune disease and neurological disease that have high medical needs as our priority areas of research, to develop new pharmaceuticals that will provide new treatment options with innovation to the frontline of healthcare. For this, we will strengthen and enhance research and drug discovery alliance with world-leading universities, research institutes, and biopharmaceutical companies in specific research areas so that we can expand our development pipeline aiming first-in-class drugs with high originality. We will also drive forward activities in areas with great medical needs, by in-licensing innovative compounds and acquiring novel technologies.

(c) Globalizing Business
To supply the world with new drugs that we have created, we are reinforcing overseas business expansion in anticipation of our own overseas marketing of specialty products such as anticancer drugs and other specialty medicines. In South Korea and Taiwan, we have already set up wholly owned subsidiaries and have started selling our products. We are also working to improve and strengthen our development and other systems, with a view to future marketing through our own sales organizations in America and Europe.

(d) Strengthening Corporate Infrastructure
We continue to reinforce our operational infrastructure, which we need to achieve in order to expand our overseas business and to continuously beat off the intense competition with other companies. We need to adapt to diverse changes in our business environment and eliminate competition. For this purpose, we must train human resources and encourage diversity so that we can have a stronger framework for development. In addition, we will fulfill our social responsibility toward all stakeholders through our activities.

(4) Basic Policy Concerning Dividends

We consider the redistribution of profits to shareholders as a vital management policy.
In terms of dividend pay-out, we will prioritize stable dividend distribution in the medium to long term.
While taking into account of our business results, we will make appropriate distribution of our profits.